Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial

Documenti analoghi

• Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG)
  di: Koji Nagafuji, et al.
  Pubblicazione: (2025)
• Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma
  di: Yasuo Mori, et al.
  Pubblicazione: (2024)
• Synergistic potential of CDK4/6 inhibitors and ATRA in non‐APL AML
  di: Rafał Skopek, et al.
  Pubblicazione: (2025)
• Extramedullary Relapse of Acute Promyelocytic Leukaemia (APL) at an Unusual Site (External Auditory Canal)
  di: Prathima Iyer, et al.
  Pubblicazione: (2025)
• Indirect presentation of mismatched human leukocyte antigen ‐B associates with outcomes of cord blood transplantation
  di: Takeshi Sugio, et al.
  Pubblicazione: (2025)